Clinically, the combined treatment of NF-κB inhibitor with TNF-α or with chemotherapeutic agents containing NF-κB-activated effect may offer a new strategy for the treatment of a variety of human cancers that are resistant to TNF-α or chemotherapy treatment alone. This evidence concerns the gene TNF and cancer.